Animal health company ImmuCell Corp. (NASDAQ: ICCC) of Portland closed its full-year and fourth quarter 2015 with strong sales, which in turn created a backlog of orders for its First Defense product to prevent diarrhea and dehydration in newborn calves. Total sales increased 22% to $2.7 million in the fourth quarter of 2015 ended Dec. 31 compared to $2.2 million in the same period last year. That marked the 14th consecutive quarter of positive sales growth over the last 21 quarters compared to the same quarters the prior years. Net income in Q4 rose to $289,000, or 9 cents per diluted share, versus net income of $131,000, or 4 cents per diluted share, in 4Q2014. Read full story
Related Posts
Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming
Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...
UNE retains R2 Research status, reinforcing leadership in scientific advancement
The University of New England has retained its status as one of the country’s leading research universities with the recent release...
Maine college students investigate health effects of forever chemicals
Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...